PTPN6 and melanoma: Considering the relevance of the immune infiltrate in supporting melanoma progression, targeting SHP-1 with specific inhibitors could be a promising novel strategy to improve the efficacy of cytokine therapy and immunotherapy, which are among the most successful approaches in clinical use for melanoma treatment [201,202].